For Quick Alerts
For Daily Alerts

Vijay Mallya Quits As Chairman Of Sanofi India

By Super

Mumbai, March 24 (IANS) Beleaguered business tycoon Vijay Mallya has decided to step down as the chairman of pharma major Sanofi India, nearly 33 years after he assumed the post, the company said in a statement here.

Mallya conveyed his decision not to seek re-election as a director at the company's ensuing Annual General Meeting, said the Sanofi statement issued late Wednesday.

Mallya had first joined in December 1973 as director of Sanofi India Ltd (SIL), then known as Hoechst Pharmaceuticals Ltd. He functioned as the board chairman since December 1983.


Also read: The Fate Of 6 Companies That Vijay Mallya Once Owned

Vijay Mallya Quits As Chairman Of Sanofi India
Sanofi India: Quotes, News
BSE 6075.00BSE Quote99.85 (1.64%)
NSE 6052.80NSE Quote72.25 (1.19%)

"I have been privileged to preside over the Board of this Company, which started as Hoechst Pharmaceuticals Ltd. and to have participated in its phenomenal growth and prosperity over such an extraordinarily long period of time," Mallya said in a farewell statement.

He described SIL as not only financially strong but with an impeccable track record and it was gratifying that it continued serving needy patients in India with world-class medication while ensuring consistent returns to all stakeholders.

SIL Managing Director Shailesh Ayyangar said under Mallya's leadership, in the past 10 years, SIL's sales grew from Rs.800 crore to Rs.2,000 crore, share price shot up from Rs.1,655 to Rs.4,358, market cap has almost tripled and the employee strength more than doubled from 1,500 to 3,700.

The SIL announced plans to induct Aditya Narayan and Usha Thorat as two new independent directors for five years from April 30, 2016.

Subject to fulfilling all requirements, Narayan, 64, is slated to take over as the next SIL Chairman in place of Mallya.

Listed on both BSE and NSE, SIL's parent company Sanofi has 60.4% equity stake in this legal entity, and its portfolio includes pharmaceuticals and consumer healthcare products.


In pharma, SIL has a strong presence in diabetes, being the only company with a balanced oral and insulin portfolio.

Read more about: vijay mallya sanofi india
Company Search
Get Instant News Updates
Notification Settings X
Time Settings
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more